CERO THERAPEUTICS HOLDINGS, INC.

CERO Therapeutics Holdings, Inc. (Nasdaq: CERO) is a clinical-stage biopharmaceutical company focused on developing chimeric engulfment receptor T-cell (CER-T) therapies for the treatment of cancer, with an initial emphasis on myeloid malignancies. The company became publicly traded through its business combination with Phoenix Biotech Acquisition Corp (PBAX), a blank-check company sponsored by Phoenix Biotech Sponsor, LLC, which completed its IPO in 2021. The June 2026 Form 424B3 prospectus filing relates to the resale of shares issued in connection with the de-SPAC transaction and subsequent financings, reflecting the company's continued capital markets activity as it advances its oncology pipeline. For complete filing history, ownership data, and warrant tracking on CERO and hundreds of other SPAC-derived companies, create a free account at SpacDesk.